uniQure’s (QURE) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of uniQure (NASDAQ:QUREFree Report) in a research report released on Tuesday morning,Benzinga reports. They currently have a $25.00 target price on the biotechnology company’s stock.

A number of other research firms have also weighed in on QURE. Cantor Fitzgerald boosted their price objective on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday. StockNews.com raised uniQure to a “sell” rating in a research note on Thursday, October 17th. The Goldman Sachs Group lowered their price objective on uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday, November 6th. Royal Bank of Canada dropped their target price on uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Finally, Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $20.00 to $52.00 in a research note on Tuesday. One analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $27.33.

View Our Latest Report on uniQure

uniQure Price Performance

Shares of NASDAQ:QURE opened at $15.30 on Tuesday. uniQure has a one year low of $3.73 and a one year high of $17.39. The stock has a market cap of $745.72 million, a PE ratio of -3.08 and a beta of 0.89. The business’s fifty day moving average price is $6.42 and its two-hundred day moving average price is $6.15. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

uniQure (NASDAQ:QUREGet Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. On average, analysts forecast that uniQure will post -3.74 EPS for the current fiscal year.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of QURE. Vanguard Personalized Indexing Management LLC increased its position in shares of uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,306 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares during the period. Geode Capital Management LLC increased its holdings in uniQure by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after purchasing an additional 6,362 shares in the last quarter. American Century Companies Inc. raised its position in uniQure by 14.6% in the second quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 8,642 shares during the period. Finally, RTW Investments LP acquired a new position in shares of uniQure during the third quarter worth about $49,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

(Get Free Report)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

Recommended Stories

Analyst Recommendations for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.